Kynexis
Kees Been is a Chief Executive Officer with a strong background in the biotech industry. With experience at companies such as Biogen, EnVivo Pharmaceuticals, and Lysosomal Therapeutics Inc, Kees has demonstrated expertise in overseeing the development of novel treatments for neurodegenerative diseases. Recently, Kees has been involved in leading Paros Bio, a biotech start-up focused on developing a treatment for Autosomal Dominant AD by normalizing Gamma-Secretase function with Presinilin 1 (PS1) gene therapy. With a solid educational background including an MBA from INSEAD and a Masters in Molecular Biology and Process Engineering from the University of Agriculture, Wageningen, Kees has a strong foundation in both business and scientific aspects of the biotech industry.
This person is not in any offices
Kynexis
Kynexis is advancing precision therapeutics for brain diseases by taking a biomarker-based approach to advance a potential first-in-class treatment for cognitive impairment associated with schizophrenia (CIAS). By harnessing large data to identify and stratify patients based on the underlying causal human. biology of the disease, Kynexis is targeting KAT-II, a key enzyme in the kynurenine pathway. The company’s lead candidate, KYN-5356, is a first-in-class small molecule that is potent and highly selective for KAT-II.